Navigation Links
Study: EBV Mononucleosis Risk Increased by Smoking and Family Size; polyDNA Recommends Gene-Eden-VIR Against the Latent EBV
Date:7/21/2013

Rochester, NY (PRWEB) July 21, 2013

A new study has shown that people living in large households or in families with smokers are at a significantly higher risk of Epstein Barr Virus (EBV) infection. EBV is well-known as the virus that can cause Mononucleosis, also known as the “kissing disease.”(1)

This rise in the risk of infection is due to the fact that smoking harms the immune system, allowing the EBV to attack the body and infect it more effectively. Further, people living in crowded homes have a higher chance of coming into contact with someone already infected with the virus. These crowded conditions can also lead to infectious mononucleosis since “Persons with infectious mononucleosis may be able to spread the infection to others for a period of weeks.” (CDC) (2)

The researchers wrote that “Environmental factors associated with socioeconomic status, such as household crowding or use of public transportation, could contribute directly to exposure risk. Suppressed immune function as a result of stress, poor nutrition, smoking, or other environmental exposures could increase susceptibility to infections given equal levels of exposure.” (1)

The CDC notes that “In the United States, as many as 95% of adults between 35 and 40 years of age have been infected.” And, “When infection with EBV occurs during adolescence or young adulthood, it causes infectious mononucleosis 35% to 50% of the time.” (2)

EBV establishes a lifelong dormant (latent) infection in some cells of the body's immune system and can lead to various diseases over time. How can an infected person help prevent the latent EBV from causing problems later in life?

polyDNA recommends that individuals concerned about the risk of EBV infection stop smoking. In addition, because EBV is so common, everyone should consider using Gene-Eden-VIR, a natural anti-EBV remedy, to boost the immune system against the latent virus.

Gene-Eden-VIR recently underwent a post marketing clinical study in which 70% of Gene-Eden-VIR users reported a reduction in viral symptoms.(3) The results of this study can seen here: http://www.cbcd.net/Gene-Eden-VIR-Clinical-Study.php

The key to your health is to reduce the level of latent viruses in your body to harmless levels.” – Dr. Hanan Polansky

To learn more about Gene-Eden-VIR and the Epstein Barr Virus, visit: http://gene-eden-kill-virus.com/EBV.php

References:

(1)    http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3661547/
(2)    http://www.cdc.gov/ncidod/diseases/ebv.htm
(3)    http://www.cbcd.net/Gene-Eden-VIR-Clinical-Study.php

###

polyDNA is a biotechnology company that develops dietary supplements using the unique scientific method developed by Dr. Hanan Polansky, which is based on Computer Intuition.

In addition to his unique scientific method, Dr. Polansky published the highly acclaimed scientific discovery, called Microcompetition with Foreign DNA. The discovery explains how foreign DNA fragments, and specifically, DNA of latent viruses, cause most major diseases.

polyDNA developed Gene-Eden-VIR, an antiviral natural remedy that helps the immune system kill latent viruses.

Read the full story at http://www.prweb.com/releases/2013/7/prweb10949092.htm.


'/>"/>
Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related medicine news :

1. New Study: Alcohol Drinkers May Face Long Term Health Issues
2. Beaumont Study: Nerve Stimulation Helps with Overactive Bladder
3. Study: Ipilimumab Shows Durable Responses But Low Overall Response Rate In Patients With Unresectable Or Metastatic Mucosal Melanoma
4. A pan-European study: Signs of motor disorders can appear years before disease manifestation
5. Study: Older Whooping Cough Vaccine More Effective
6. Study: Peer-referral programs can increase HIV-testing in emergency departments
7. Study: Patient openness to research can depend on race and sex of study personnel
8. Study: Brain makes call on which ear is used for cell phone
9. Study: HIV Infection Does Not Adversely Affect Outcomes of Liver Transplantation for Hepatocellular Carcinoma
10. Penn pilot study: Group of Bradford Co, Pa. residents concerned about health effects of hydrofracking
11. Great HealthWorks, Inc., makers of Omega XL, Report New Independent Study: Omega-3 DHA Protects Against Liver Disease
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/10/2016)... ... February 10, 2016 , ... Intermedix ... of Emergency Medicine , an emergency medicine professional association, to support the organization's ... , The American Academy of Emergency Medicine, or AAEM, seeks to empower emergency ...
(Date:2/10/2016)... , ... February 10, 2016 , ... Emergency rooms provide ... to find. Unfortunately, this can leave patients with dental emergencies at risk of losing ... now offering emergency dental care. , Common dental emergencies include:, ...
(Date:2/10/2016)... ... February 10, 2016 , ... Dr. Jessica Barron, of ... is now accepting new dental patients and families in the North Metro Denver area. ... services from cleanings to cosmetic dentistry, and all in the most relaxing environment. , ...
(Date:2/10/2016)... , ... February 10, 2016 , ... ... organization, welcomes S.S. Nesbitt as the latest addition to its growing list of ... other locations throughout the Southeast, from Orlando to Huntsville and in between. , ...
(Date:2/10/2016)... ... , ... Armune BioScience signed a definitive agreement with ARCpoint ... across the country. Launched in April of 2015, Apifiny is the only cancer specific, ... order volume exceeded 3,000 tests in 2015. Primary care physicians and urologists have utilized ...
Breaking Medicine News(10 mins):
(Date:2/10/2016)... LONDON , February 10, 2016 A new report ... 2021 - states that the Alzheimer,s disease market will more than double ... 2021, at a Compound Annual Growth Rate (CAGR) of 11%. ... Italy , Spain , the UK, and ... prevalence during the forecast period. --> Canada , ...
(Date:2/10/2016)... SAN DIEGO , Feb. 10, 2016 ... viral gene therapy manufacturing, and Renova™ Therapeutics, a biopharmaceutical ... and other chronic diseases, have entered into a Manufacturing ... produce cGMP-grade RT-100 (Ad5.hAC6) Drug Product for use in ... --> This relationship will leverage Lonza,s ...
(Date:2/10/2016)... , Feb. 10, 2016 Immune Pharmaceuticals Inc. ... announced today that it has filed a patent application ... other cancers. --> --> ... by administration of Ceplene (histamine dihydrochloride) in combination with ... of predicting the efficacy of Ceplene and IL-2 therapy ...
Breaking Medicine Technology: